16 results about "Progressive renal failure" patented technology

The mechanisms driving the development of extracapillary lesions in focal segmental glomerulosclerosis (FSGS) and crescentic glomerulonephritis (CGN) remain poorly understood. A key question is how parietal epithelial cells (PECs) invade glomerular capillaries, thereby promoting injury and kidney failure. Here the inventors show that expression of the tetraspanin CD9 increases markedly in PECs in mouse models of CGN and FSGS, and in kidneys from individuals diagnosed with these diseases. Cd9 gene targeting in PECs prevents glomerular damage in CGN and FSGS mouse models. Mechanistically, CD9 deficiency prevents the oriented migration of PECs into the glomerular tuft and their acquisition of CD44 and β1 integrin expression. These findings highlight a critical role for de novo expression of CD9 as a common pathogenic switch driving the PEC phenotype in CGN and FSGS, while offering a potential therapeutic avenue to treat these conditions. Accordingly, CD9 represents a reliable biomarker and as well as a biotargets in glomerulonephritides.

The present invention provides methods of using non-naturally occurring melanocortin analogs to increase body weight and / or increase food consumption in a subject having a kidney disease and / or a liver disease (e.g., chronic kidney disease, renal failure, non-alcoholic fatty liver disease (NAFLD)). Also provided are methods of stimulating appetite in a subject via administration of a non-naturally occurring melanocortin analogue. The non-naturally occurring melanocortin analogs may be present in pharmaceutical compositions and delivered via parenteral administration (e.g., subcutaneous injection). The methods improve appetite, increase food consumption, increase body weight, muscle mass, and / or fat mass in the subject.

The application discloses a hemodialysis sufficiency evaluation method based on sodium balance, and relates to the technical field of hemodialysis, and the method comprises the following steps: obtaining the body weight, dry body weight and serum sodium concentration of a patient before dialysis; calculating a target sodium removal amount Na_target=DeltaW* [Na]s / 0.93, and establishing a quantitative equivalent relationship between the body weight increase and sodium accumulation; obtaining or calculating an actual sodium removal amount (including two ways of convection and diffusion); calculating a sodium removal ratio R_Na=Na_actual / Na_target; and evaluating the dialysis sufficiency according to the R_Na. The application firstly changes the dialysis sufficiency evaluation from 'urea removal' to'sodium and water removal', and directly aims at the main pathological burden of kidney failure patients, i.e. sodium and water retention. The sodium removal ratio R_Na is more directly related to the volume state and cardiovascular prognosis of the patient than the traditional Kt / V index. The method only needs the body weight and serum sodium before and after dialysis to be calculated, and can be integrated into the existing dialysis information system.

The disclosure provides means, methods, and compositions of preventing, reducing, and treating kidney failure through the administration of fibroblasts, modified fibroblasts, and / or products derived from fibroblasts. The disclosure may also concern administration of fibroblasts prior to, concurrent with, or subsequent to administration of a nephrotoxic agent results in production of renal function. In some embodiments, fibroblasts are enhanced for augmentation of nephron-regenerative properties through culture under means including hypoxia, histone deacetylase inhibitor treatment, oxytocin, and / or DNA methyltransferase inhibitors.

The present invention provides novel 2,4-dinitrophenol (DNP) derivatives and prodrugs thereof as modulators of mitochondrial function. The present invention also provides pharmaceutical compositions comprising the compounds of the present invention and methods for using the same to treat various diseases and conditions associated with or related to mitochondrial dysfunction (e.g., obesity, diabetes, insulin resistance, liver disease, heart or kidney failure, neurodegenerative diseases, and aging-related diseases, including but not limited to sarcopenia, osteoporosis, etc.).

The invention provides a peritoneal dialysis device for renal failure, and belongs to the technical field of peritoneal dialysis. Comprising a positioning disc, an in-vivo dialysis tube, an in-vitro dialysis tube and a buffering assembly, the in-vivo dialysis tube and the in-vitro dialysis tube are installed on the positioning disc, the buffering assembly is used for buffering traction force on the in-vitro dialysis tube, the buffering assembly is further used for supporting and positioning the in-vivo dialysis tube, and the buffering assembly is connected with the positioning disc and a positioning plate. By arranging the buffer assembly, the in-vivo dialysis tube can be plastically fixed, the phenomenon that the in-vivo dialysis tube deviates and floats upwards after being used in the body of a patient for a long time is prevented, the difficulty of peritoneal dialysis operation of the patient is reduced, redundant in-vitro dialysis tubes outside the body of the patient can be stored, and the in-vivo dialysis tube fixing device is convenient to use. When the extracorporeal dialysis tube is pulled, the buffering assembly can absorb and buffer the pulling force at the first time, the situation that the pulling force directly acts on the skin of a patient, and consequently the patient feels uncomfortable is avoided, and the safety of the peritoneal dialysis device in daily use is improved.

Metal-organic framework molecules with pyrene group-containing or biphenyl group-containing linkers for use in the removal of uremic toxins from biological samples that contain such toxins are provided. Also provided are methods for using the MOFs to remove uremic toxins from biological samples. The methods include hemodialysis of blood samples from patients suffering from a uremia-related disease, such as chronicap kidney failure.

Autosomal Dominant Polycystic Kidney Disease (ADPKD) is characterized by hundreds of fluid filled cysts that form in the kidney, resulting in kidney failure. Cysts form when the PKDl gene is inactivated. The present disclosure has found a specific target for therapy, an alternative DNA structure called G4 DNA in the PKDl gene is responsible for cyst formation. G4 DNA is a targetable structure, so the present disclosure provides specific nucleic acid inhibitors of G4 formation, and G4 structure destabilization, thereby blocking G4 DNA and cyst formation in at risk individuals for developing polycystic kidney disease, for example, ADPKD.

Compositions consist essentially of trigonelline or consist of trigonelline. The compositions can be used in food or beverage applications, pharmaceutical formulations, or as a dietary supplement. The compositions can be administered to a mammal to treat or prevent a mitochondria-related disease or a condition associated with altered mitochondrial function in an individual in need thereof or at risk thereof. The mitochondria-related disease or condition is selected from the group consisting of deleterious effects of aging, stress (e.g., oxidative stress), obesity, overweight, reduced metabolic rate, metabolic syndrome, diabetes mellitus, complications from diabetes, hyperlipidemia, neurodegenerative disease, cognitive disorder, stress-induced or stress-related cognitive dysfunction, mood disorder, anxiety disorder, age-related neuronal death or dysfunction, chronic kidney disease, kidney failure, trauma, infection, cancer, hearing loss, macular degeneration, myopathies and dystrophies, and combinations thereof.

Disclosed herein is a method of treating cachexia in a subject. According to some embodiments of the present disclosure, the method includes administering to the subject an effective amount of a recombinant antibody or a fragment thereof, which exhibits a binding affinity and a neutralizing effect on parathyroid hormone-related protein. According to certain embodiments of the present disclosure, the cachexia is caused by a parathyroid hormone-related protein (PTHrP)-expressing cancer, chronic kidney disease, kidney failure, heart failure, or tuberculosis.

The invention discloses clostridium pralaense for improving the intestinal barrier function of a mouse with chronic kidney disease and application of the clostridium pralaense, and belongs to the technical field of microorganisms and the technical field of medicines. The clostridium prausnitzii CCFM1204 provided by the invention has beneficial effects in delaying the renal failure process, can significantly improve kidney pathological characteristics of mice with adenine-induced chronic nephropathy, reduce the serum urea nitrogen level, reduce the collagen volume fraction of kidney tissues, improve the intestinal barrier function, and can be used for preventing and treating the chronic nephropathy of the mice with adenine-induced chronic nephropathy, so that the clostridium prausnitzii CCFM1204 can be used for preventing and treating the chronic nephropathy of the mice with adenine-induced chronic nephropathy of the mice with adenine-induced chronic nephropathy. The serum LPS level and the expression quantity of proinflammatory factors in the colon tissue are reduced, and the expression quantity of tight junction proteins in the colon tissue is improved. The clostridium praeparatum CCFM1204 provided by the invention has a wide application prospect in preparation of drugs for relieving or improving intestinal barrier dysfunction related to chronic kidney diseases.

The disclosure provides means, methods, and compositions of preventing, reducing, and treating kidney failure through the administration of fibroblasts, modified fibroblasts, and / or products derived from fibroblasts. The disclosure may also concern administration of fibroblasts prior to, concurrent with, or subsequent to administration of a nephrotoxic agent results in production of renal function. In some embodiments, fibroblasts are enhanced for augmentation of nephron-regenerative properties through culture under means including hypoxia, histone deacetylase inhibitor treatment, oxytocin, and / or DNA methyltransferase inhibitors.

Compounds described herein may be used for the treatment of neurodegenerative diseases linked to protein misfolding, including prion diseases, Alzheimer's disease, Parkinson's disease (PD) and amyotrophic lateral sclerosis (ALS), and also other neurodegenerative, degenerative, metabolic and ischemic conditions. Indeed, NAD metabolism impairment is also a critical feature in brain ischemia / reperfusion injury, Wallerian degeneration, kidney failure, multiple sclerosis, aging, and metabolic disorders such as diabetes mellitus. Therapies that elevate or stabilize NAD levels may thus have broad potential for treating many severely debilitating neurological and metabolic conditions. Evidence is provided herein with compounds from 8 lead series for NAD restoring properties and for therapeutic efficacy in cellular and / or animal models of prion disease, PD and ALS.

The invention relates to the technical field of dialysis treatment, and discloses a renal failure patient peritoneal dialysis fluid circulation heating and filtering integrated device which comprises a dialyzer, a mounting groove is formed in the position, below a heating groove, of the inner wall of the dialyzer, a heating pipe is mounted on the inner wall of the mounting groove, and a plurality of surrounding type flow guide pipes are mounted on the inner wall of the heating groove at equal intervals. A butt joint hopper is fixedly arranged at one end of each surrounding type flow guide pipe, and a partition plate is fixedly installed at one end of the inner wall of the heating groove. Dialysate flows in the surrounding type flow guide pipes, the flowing distance of the dialysate and the retention time of the dialysate in the heating groove are both increased, and enough time is provided for temperature rise; the heated dialysate enters the other end of the inner wall of the heating groove through the through holes in the partition plate and is discharged, the dialysate is guided into the abdomen of the patient through the dialysis connecting assembly for dialysis treatment, the dialysate can be kept at the temperature close to the body temperature of the patient for dialysis, redundant materials of the kidney of the renal failure patient can be more quickly dialyzed and filtered out, and the treatment efficiency is improved. And the dialysis treatment effect is improved.

The invention relates to the technical field of medicine, in particular to a column diagram model for predicting renal function prognosis of a CKD patient and an establishment method. The invention provides a column diagram model for predicting the probability that a CKD patient does not suffer from renal failure in 1, 2 and 3 years and an establishment method of the column diagram model, five risk factors including hypertension, mesangial hyperplasia degree, renal tubule atrophy degree, blood potassium and glomerular filtration rate are screened out from the column diagram model, and the five risk factors are used for establishing the column diagram model. In the training queue, the C index is 0.898, and the AUC values of the first year, the second year and the third year are 0.983 (95% CI 0.966-1.000), 0.955 (95% CI 0.924-0.986) and 0.945 (95% CI 0.918-0.972) respectively. In the external verification queue, the C index is 0.918, and the corresponding AUC values of the first year, the second year and the third year are 0.919 (0.853 to 0.986), 0.902 (0.822 to 0.982) and 0.915 (0.846 to 0.985). The calibration curve and the DCA curve show that the accuracy of the model is in a fitting range, which shows that the column graph model has good prediction capability.

This invention relates to a device and medium for assessing the risk of inadequate bowel preparation in patients taking oral magnesium sulfate. The device includes: a data acquisition module for acquiring various risk assessment indicators for patients taking oral magnesium sulfate, including indicators of stroke or dementia, inflammatory bowel disease, heart or kidney failure, colonic stenosis, medication history, dietary type, taste of laxatives, preferred laxatives, history of failed bowel preparation, adverse events, complete administration, and yellow watery stools; and a bowel preparation inadequate risk assessment module for assigning values ​​to the acquired risk assessment indicators to assess the risk of inadequate bowel preparation. Compared with existing technologies, this invention has the advantages of comprehensively and accurately assessing the risk of inadequate bowel preparation, and has good discrimination and calibration.